Michael Davidson to Antibodies, Monoclonal
This is a "connection" page, showing publications Michael Davidson has written about Antibodies, Monoclonal.
Connection Strength
1.838
-
Clinical trials. Curr Opin Lipidol. 2018 06; 29(3):277-278.
Score: 0.361
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.353
-
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
Score: 0.351
-
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013 Nov; 10(11):618-9.
Score: 0.260
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 Jul; 45(7):1310-1315.
Score: 0.147
-
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
Score: 0.092
-
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
Score: 0.081
-
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
Score: 0.063
-
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
Score: 0.054
-
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer. 2021 06; 156:147-150.
Score: 0.028
-
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2021 02 25; 2(2):224-235.
Score: 0.027
-
Monoclonal antibodies to proteins from cocksfoot grass (Dactylis glomerata) pollen: isolation and N-terminal sequence of a major allergen. Int Arch Allergy Appl Immunol. 1990; 91(4):419-25.
Score: 0.013
-
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
Score: 0.005
-
Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
Score: 0.004